A benchmarking analysis of 20 FDA-approved diabetes drugs found that the three most efficient were all GLP-1 peptides — oral semaglutide, injectable semaglutide, and dulaglutide.
Top 3 are all GLP-1Oral semaglutide, injectable semaglutide, and dulaglutide achieved maximum medication efficiency among 20 FDA-approved diabetes drugs
What the researchers found
Oral semaglutide, subcutaneous semaglutide, and dulaglutide achieved the highest medication efficiency scores among 20 T2D drugs, while lixisenatide and liraglutide scored lower despite being in the same GLP-1 class.
Why it matters
With 20+ diabetes drug options, understanding which ones deliver the most benefit per dose helps both patients and clinicians make better treatment decisions. The dominance of GLP-1 peptides confirms their position as the most effective modern diabetes drug class.
The numbers in context
Analysis covers tens of FDA-approved diabetes drugs from the 1950s through present day.
How the study worked
Data envelopment analysis (DEA) model using FDA data and meta-analysis results. Evaluated 20 T2D drugs on benefits (glucose lowering, weight loss) and harms (mortality) relative to dosing frequency. Used directional distance function to handle multidimensional outcomes.
Who was studied
Analysis of all FDA-approved diabetes drugs from 1950s to present
What this study cannot tell us
DEA efficiency models involve methodological choices about input/output weighting. Newer drugs have less long-term safety data. Analysis does not account for cost, which is a major real-world treatment factor. Some drugs serve different clinical niches that simple efficiency rankings may not capture.
How to read the evidence
Moderate evidence: novel analytical approach using FDA data and meta-analysis results, but methodology involves modeling assumptions and does not replace clinical trial comparisons.
When this study was published
Published in 2024. Covers the full history of FDA-approved diabetes drugs from the 1950s through present.
The bigger picture
The diabetes treatment landscape has fundamentally shifted. Drugs approved before 2010 focused narrowly on blood sugar, while modern GLP-1 peptides deliver glucose control, weight loss, and cardiovascular protection in a single weekly (or daily oral) dose. This efficiency analysis quantifies that paradigm shift and demonstrates why GLP-1 drugs have become the standard of care.
Questions still open
- Would including cost data change the efficiency rankings, given the high price of GLP-1 drugs?
- How would newer drugs like tirzepatide rank in this framework?
- Why do some GLP-1 drugs (lixisenatide, liraglutide) score lower than others despite targeting the same receptor?
Common questions
Why are GLP-1 drugs more efficient than older diabetes medications?
Are all GLP-1 drugs equally effective?
Read the original research
Benchmarking the medication efficiency and technological progress of diabetes drugs.
Frontiers in public health, 12, 1396832
Citation
Zhang, Hongwei; Wang, Chen; Xu, Ting; Liu, Lin; Ban, Xuyan; Liu, Weijie; Yan, Chenli; Han, Xiaodong. (2024). Benchmarking the medication efficiency and technological progress of diabetes drugs.. Frontiers in public health, 12, 1396832. https://doi.org/10.3389/fpubh.2024.1396832